EUVIMEDEUVIMED entdecken
Metaanalyse

Efficacy and safety of sunitinib in treatment of advanced or metastatic pheochromocytomas and paragangliomas: a meta-analysis of sunitinib-treated arms from prospective clinical trials

Alejandro Román-González iD, Carlos Esteban Builes-Montaño, Wellgner Fernandes Oliveira Amador, Marta Araujo-Castro iD, Camilo Jimenez iD

The Journal of Clinical Endocrinology & Metabolism · 30.10.2026

DOI: 10.1210/clinem/dgag446 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 30.10.2026. Verfasst von Alejandro Román-González und 4 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology and Diabetes Section. Departamento de Medicina Interna. Facultad de Medicina Universidad de Antioquia, Medellin, Colombia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Metastatic pheochromocytomas and paragangliomas (mPPGLs) are rare neuroendocrine tumors with limited treatment options. Among the options for the treatment of mPPGLs are tyrosine kinase inhibitors (TKIs), including cabozantinib and sunitinib. However, TKIs have different molecular targets and side effects. Additionally, the evidence supporting their use for these tumors has been limited and of low quality.

Objective

To summarize prospective efficacy and safety outcomes of sunitinib among patients with mPPGLs.

Methods

A literature search was conducted to investigate the effects of sunitinib on progression-free survival (PFS) tumor responses and adverse events (AEs) in prospective studies of sunitinib for mPPGL treatment. Because only one included study had a comparator, quantitative synthesis was performed at the sunitinib-treatment-arm level.

Results

Three prospective clinical trials were included in the meta-analysis. The total sample in these studies was 114 patients given sunitinib. The objective response rate was 21.2% (95% CI, 11.7-35.3%), and all the responses were partial, with no complete responses. The stable disease rate was 51.8% (95% CI, 36.8-66.4%). The progressive disease rate was 27.1% (95% CI, 19.5-36.3%). The 12-month PFS rate was 48.2% (95% CI, 38.1-58.5%). The median PFS duration was 11.9 months (95% CI, 6.9-16.9 months). The rate of treatment discontinuation due to AEs was 13.2% (95% CI, 8.1-20.7%). The rate of grade ≥3 adverse events was 57.8% (95% CI, 36.7-76.4%), with substantial heterogeneity (I2 = 86%; P = .001).

Conclusion

Overall, the available low to very low certainty but prospective evidence suggests that sunitinib provides clinically relevant disease control in a subset of patients, characterized by modest objective response rates.

Schlagwörter

Stichwörter der Autor:innen

cabozantinibparagangliomapheochromocytomasunitinib

Autor:innen und Institutionen

  • Endocrinology and Diabetes Section. Departamento de Medicina Interna. Facultad de Medicina Universidad de Antioquia, Medellin, Colombia.
  • Department of Internal Medicine, Hospital Pablo Tobón Uribe, Medellín, Colombia.
  • Universidad Federal de Campina Grande, Cajazeiras, Brazil.
  • Endocrinology & Nutrition Department, Ramón y Cajal Hospital, 28034 Madrid, Spain 2 5. Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), 28034 Madrid, Spain.
  • Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, TX 77030, USA.

ORCID-Profile: Alejandro Román-González, Marta Araujo-Castro, Camilo Jimenez

Zitieren

APA

Román-González, A., Builes-Montaño, C. E., Amador, W. F. O., Araujo-Castro, M., & Jimenez, C. (2026). Efficacy and safety of sunitinib in treatment of advanced or metastatic pheochromocytomas and paragangliomas: a meta-analysis of sunitinib-treated arms from prospective clinical trials. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag446

Vancouver

Román-González A, Builes-Montaño CE, Amador WFO, Araujo-Castro M, Jimenez C. Efficacy and safety of sunitinib in treatment of advanced or metastatic pheochromocytomas and paragangliomas: a meta-analysis of sunitinib-treated arms from prospective clinical trials. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag446

BibTeX
@article{RomnGonzlez2026,
  author = {Román-González, Alejandro and Builes-Montaño, Carlos Esteban and Amador, Wellgner Fernandes Oliveira and Araujo-Castro, Marta and Jimenez, Camilo},
  title = {Efficacy and safety of sunitinib in treatment of advanced or metastatic pheochromocytomas and paragangliomas: a meta-analysis of sunitinib-treated arms from prospective clinical trials},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgag446}
}
Kostenlos starten →